Novo Nordisk A/SNVONYSE
Loading
Income Tax Expense Over TimeStrong
Percentile Rank100
3Y CAGR+25.9%
5Y CAGR+19.7%
Year-over-Year Change
Income taxes paid or accrued
3Y CAGR
+25.9%/yr
vs +10.8%/yr prior
5Y CAGR
+19.7%/yr
Recent acceleration
Acceleration
+15.1pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
7 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $27.03B | +3.1% |
| 2024 | $26.20B | +24.8% |
| 2023 | $20.99B | +55.1% |
| 2022 | $13.54B | +19.6% |
| 2021 | $11.32B | +3.0% |
| 2020 | $10.99B | +14.5% |
| 2019 | $9.60B | +6.8% |
| 2018 | $8.99B | -14.8% |
| 2017 | $10.55B | +6.9% |
| 2016 | $9.87B | - |